2024-11-28 - Analysis Report
## Johnson & Johnson (JNJ) Stock Review

This report analyzes Johnson & Johnson (JNJ), a leading healthcare company, based on the provided data.  We will assess its performance relative to the S&P 500 (VOO), examine recent price movements, technical indicators, financial statements, and recent news.

**1. Performance Relative to S&P 500:**

Johnson & Johnson's cumulative return of 37.36% significantly underperforms the S&P 500's 128.86% cumulative return over the analyzed period. The difference is -91.5%, placing it at the 2.5th percentile of its historical range of underperformance relative to the S&P 500 (-94.3% to 17.1%).  This suggests JNJ has lagged significantly behind the broader market. The provided CAGR data shows consistent but comparatively lower returns than the market throughout the periods analyzed, further confirming the underperformance.


**2. Recent Price Movement:**

* **Closing Price:** $155.4
* **5-Day Moving Average:** $154.53
* **20-Day Moving Average:** $154.42
* **60-Day Moving Average:** $159.33

The price is currently below all three moving averages, indicating a potential short-term bearish trend.  The 60-day MA suggests a more significant pullback from recent highs.

**3. Technical Indicators:**

* **RSI (49.72):**  Near the neutral level of 50, suggesting neither overbought nor oversold conditions.
* **PPO (0.28):** Slightly positive, implying a potential bullish momentum, but weak.
* **20-Day Relative Strength Divergence (-3.2):** Indicates a recent weakening of relative strength compared to the S&P 500.
* **Expected Return (0.0%):**  The model projects no significant outperformance relative to the S&P 500 over the long term (2+ years).  This aligns with the historical underperformance observed.  The provided price of 155.39 does not indicate any drastic recent price swings (no sudden surges or collapses).

**4. Recent Financial Performance:**

The provided EPS and revenue figures show some fluctuation. While revenue generally remains stable around $22B, EPS shows variability.  Crucially, more context is needed to interpret this data meaningfully.  Comparing EPS figures to expectations and analyzing revenue growth rates (YoY, QoQ) is essential for a proper assessment.  The significantly higher EPS in October 2023 compared to preceding quarters requires further investigation to determine if this was a one-off event or a meaningful shift in performance.


**5.  Revenue and Profitability:**

Consistent high profit margins (68-70%) demonstrate strong profitability. However, the ROE fluctuates, suggesting potential variability in shareholder return. The exceptionally high ROE of 36.54% in Q3 2023 needs further analysis to understand the underlying reasons.  This could stem from a non-recurring event that should be excluded when analyzing ongoing profitability.


**6. Capital and Profitability:**

The equity figures show relatively stable equity levels, indicating a healthy financial position. However, the variability in ROE warrants closer examination to determine the drivers behind these fluctuations.


**7. News and Recent Issues:**

(This section requires information from news sources such as Shacknews and Finbold.  Please provide recent news articles or summaries for a complete analysis.  Specifically, details regarding the October 2023 EPS surge, and analyst opinions on future performance are needed.)  Include information on any recent market outlook, analyst opinions, and key performance highlights.


**8. Overall Analysis:**

JNJ has significantly underperformed the S&P 500 over the analyzed period, exhibiting lower returns and lagging behind the market's growth.  While it maintains strong profit margins and a stable financial position, recent financial performance exhibits variability, particularly in EPS and ROE.  Technical indicators suggest a neutral to slightly bearish short-term outlook. Long-term prospects depend heavily on resolving the questions raised by the unusual October 2023 EPS and the reasons behind the ROE fluctuations. A detailed analysis of the recent earnings reports and market sentiment (obtained from sources mentioned in section 7) is crucial for a comprehensive evaluation.   The lack of a clear positive expected return underscores the need for a thorough investigation before making any investment decisions.



**9.  Next Steps:**

To enhance this analysis, further investigation is needed into the following areas:

* **Earnings Report Details:** Thoroughly review the most recent earnings reports, including analyst estimates and management commentary, to understand the reasons behind the unusual October 2023 EPS figure and the fluctuations in ROE.
* **Industry Analysis:** Compare JNJ's performance to its competitors within the healthcare industry.
* **Growth Prospects:** Analyze JNJ's future growth potential, considering factors such as innovation pipeline, regulatory changes, and market competition.
* **Valuation:** Conduct a thorough valuation analysis to assess whether JNJ is currently undervalued or overvalued.
* **Risk Assessment:** Identify and assess the key risks associated with investing in JNJ.


Only after completing this additional research can a well-informed investment decision be made.
